Parameter | Evaluated parameter | ΔCosts (SEK) | ΔEffects (QALYs) | ICER (costs per QALY gained) |
---|---|---|---|---|
Mucormycosis prevalence | 14% | 59,191 | 0.72 | 81,464 |
Pathogen identification percentage | 0% | 64,793 | 0.34 | 189,966 |
100% | 39,588 | 0.26 | 154,784 | |
Second-line treatment drug costs | −50% | 53,701 | 0.3 | 179,950 |
+ 50% | 50,681 | 0.3 | 169,830 | |
Percentage receiving second-line treatment | 0% | 42,361 | 0.3 | 141,952 |
Percentage requiring therapeutic drug monitoring | 50% for isavuconazole and 75% for voriconazole/posaconazole | 51,661 | 0.3 | 173,115 |
Percentage starting with IV formulation | 100% | 56,818 | 0.3 | 190,397 |
Life expectancy | −50% | 52,191 | 0.17 | 310,924 |
+ 50% | 52,191 | 0.40 | 130,484 |